Dermapharm Holding Se · XETR:DMP
Dermapharm — Q3 2019 Earnings Presentation
14 slides from Dermapharm's earnings presentation, Nov 20, 2019
Slide 1: Investor and Analyst Conference Call Q3 2019
Investor and Analyst Conference Call Q3 2019 Grünwald, 20 November 2019
Slide 2: Agenda
Agenda 1. Overview 2. Financial figures Q3 2019 3. Outlook FY 2019 4. Q&A
Slide 3: Agenda
Agenda 1. Overview 2. Financial figures Q3 2019 3. Outlook FY 2019 4. Q&A
Slide 4: Dermapharm – Highlights Q3 2019
Dermapharm – Highlights Q3 2019 In-house product Further development Internationalisation Change in ▪ Pipeline of 50 ongoing ▪ mibe Pharma España: Targeted Management Board development projects founding of new entity in M&A activities on track Spain in October 2019 ▪ On 1 October 2019 ▪ Fitvia: Syne
Slide 5: Agenda
Agenda 1. Overview 2. Financial figures Q3 2019 3. Outlook FY 2019 4. Q&A
Slide 6: Dermapharm Group Revenue – Significant growth in all segments
Dermapharm Group Revenue – Significant growth in all segments Dermapharm’s revenue development Dermapharm Group 9M 2018 vs 9M 2019 €m, YoY growth (%) ▪ Significant revenue growth of 20.7 % to € 517.6 million Branded pharmaceuticals & other healthcare 517.6 (1) products +20.7% ▪ Revenues up by 10.7 %
Slide 7: Dermapharm Group EBITDA
Dermapharm Group EBITDA – Disproportional growth due to successful integration of the recent acquisitions Dermapharm’s adjusted EBITDA(1) development Dermapharm Group 9M 2018 vs 9M 2019 €m, YoY growth (%) ▪ EBITDA up by 25.1 % to € 133.1 million (adjusted) and 21.4 % to € 124.6 million (unadjusted)
Slide 8: Earnings before tax (EBT)
Earnings before tax (EBT) – Reflecting successful acquisitions and investments in future growth Dermapharm’s EBT(1) development Comments 9M 2018 vs 9M 2019 €m, YoY growth (%) ▪ EBT increased by 3.3 % to € 82.6 million (unadjusted) resulting in a lower margin of 16.0 % Group EBT 18.6% 16.0% margin ▪
Slide 9: Cash flows and cash conversion
Cash flows and cash conversion – Reflecting strong dedication to future growth Cash flow and cash conversion (1) Comments in €m / in % of group EBITDA ▪ CF from operating activities in 9m 2019 below previous year because of ▪ by settlement of receivables from Themis Beteiligungs-AG Cash in the first
Slide 10: Balance sheet of Dermapharm Group
Balance sheet of Dermapharm Group Balance Sheet as of 30 September 2019 Comments in €m ▪ Total assets increased to € 1,016 million (31 December 2018: € 704.6 million) ▪ Non-current assets increased to € 700.3 million (31 December 2018: € 333.3 million) mainly due to an increase 1,016 1,016 in intang
Slide 11: Agenda
Agenda 1. Overview 2. Financial figures Q3 2019 3. Outlook FY 2019 4. Q&A
Slide 12: Growth strategy on track and in line with guidance 2019
Growth strategy on track and in line with guidance 2019 of the Annual Report 2018 Revenues ++14 % to +19 % 2019 vs. previous year (€572m) EBITDA 2019 +17 % to +22 % (adjusted) vs. previous year (€143.4m (adjusted)) “Growth rates are based on organic growth, new launches of in-house developments and
Slide 13: Investors’ and Analysts’ Conference Call Q&A
Investors’ and Analysts’ Conference Call Q3 2019 Q&A
Slide 14: Investor contact
Investor contact Britta Hamberger Investor Relations Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233